Jinfeng Xiang

机构：AstraZeneca (United Kingdom), University of Science and Technology of China, AstraZeneca (Poland), AstraZeneca (Spain)

发表论文 50 篇 · 总被引 529 次 · h-index 13

代表论文

• Constructing simplified microbial consortia that couple lactic acid and ethanol utilization to highly produce caproic acid from liquor-making wastewater (2025 · Water Research · 被引 18)
• Probiotic interventions with highly acid-tolerant Levilactobacillus brevis strains improve lipid metabolism and gut microbial balance in obese mice (2024 · Food & Function · 被引 8)
• GEMINI-Hepatobiliary: A phase 2 study of novel first-line immuno-oncology-based treatments in patients with advanced hepatobiliary cancers. (2024 · Journal of Clinical Oncology · 被引 6)
• WDR36 Regulates Trophectoderm Differentiation During Human Preimplantation Embryonic Development Through Glycolytic Metabolism (2024 · Advanced Science · 被引 5)
• First-line rilvegostomig (rilve) plus chemotherapy (CTx) in advanced biliary tract cancer (BTC): Primary analysis of GEMINI-Hepatobiliary substudy 2 Cohort A. (2025 · Journal of Clinical Oncology · 被引 3)
• Generation of transient totipotent blastomere-like stem cells by short-term high-dose Pladienolide B treatment (2025 · Science China Life Sciences · 被引 3)